Appia Bio Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
36
- Latest Deal Type
-
Series A1
- Latest Deal Amount
-
$20.5M
- Investors
-
8
Appia Bio General Information
Description
Developer of a stem cell therapy technology intended to discover and develop chimeric antigen receptor-natural killer T(CAR-NKT) cells for safe and targeted cancer treatments for patients. The company's technology matures and scales up healthy stem cells into invariant T-cell therapies, enabling physicians to have access to allogeneic off-the-shelf cell therapies.
Contact Information
Website
www.appiabio.comCorporate Office
- 6160 Bristol Parkway
- Suite 300
- Culver City, CA 90230
- United States
Corporate Office
- 6160 Bristol Parkway
- Suite 300
- Culver City, CA 90230
- United States
Appia Bio Timeline
Appia Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series A1) | 30-Aug-2024 | $20.5M | Completed | Pre-Clinical Trials | ||
| 2. Early Stage VC (Series A) | 11-May-2021 | Completed | Pre-Clinical Trials | |||
| 1. Accelerator/Incubator | 01-Jan-2021 | Completed | Pre-Clinical Trials |
Appia Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Appia Bio Comparisons
Industry
Financing
Details
Appia Bio Competitors (6)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ImmPACT Bio | Venture Capital-Backed | Los Angeles, CA | ||||
| Century Therapeutics | Formerly VC-backed | Philadelphia, PA | ||||
| Shoreline Biosciences | Venture Capital-Backed | San Diego, CA | ||||
| Adicet Bio | Formerly VC-backed | Boston, MA | ||||
| Nkarta Therapeutics | Formerly VC-backed | South San Francisco, CA |
Appia Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Appia Bio Patents
Appia Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230124097-A1 | Engineering stem cell t cells with multiple t cell receptors | Pending | 14-Oct-2021 | ||
| AU-2022366817-A1 | Engineering stem cell t cells with multiple t cell receptors | Pending | 14-Oct-2021 | ||
| CA-3235379-A1 | Engineering stem cell t cells with multiple t cell receptors | Pending | 14-Oct-2021 | ||
| EP-4416271-A1 | Engineering stem cell t cells with multiple t cell receptors | Pending | 14-Oct-2021 | ||
| CA-3220136-A1 | Production of engineered t cells from stem cells | Pending | 14-May-2021 | C12N5/0646 |
Appia Bio Executive Team (10)
| Name | Title | Board Seat |
|---|---|---|
| JeenJoo Kang Ph.D | Co-Founder, Chief Executive Officer & Board Member | |
| Jason Damiano | Chief Scientific Officer | |
| Sylvaine Cases | Chief Business Officer | |
| Lili Yang Ph.D | Scientific Co-Founder & Board Member | |
| Tessa Aglupos-McCann | Senior Director of Finance |
Appia Bio Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Daqing Cai Ph.D | Self | Board Member | |
| David Baltimore Ph.D | Self | Chairman, Advisor and Scientific Founder | |
| Francisco Gimenez Ph.D | 8VC | Board Member | |
| Irving Weissman MD | Self | Scientific Advisory Board | |
| JeenJoo Kang Ph.D | Appia Bio | Co-Founder, Chief Executive Officer & Board Member |
Appia Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Appia Bio Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Breakout Ventures | Venture Capital | Minority | ||
| 8VC | Venture Capital | Minority | ||
| Axial (San Francisco) | Venture Capital | Minority | ||
| Freeflow Ventures | Venture Capital | Minority | ||
| Kite Pharma | Corporation | Minority |
Appia Bio FAQs
-
When was Appia Bio founded?
Appia Bio was founded in 2020.
-
Who is the founder of Appia Bio?
JeenJoo Kang Ph.D, Lili Yang Ph.D, Jeffrey Wiezorek MD, Pin Wang Ph.D, and David Baltimore Ph.D are the founders of Appia Bio.
-
Who is the CEO of Appia Bio?
JeenJoo Kang Ph.D is the CEO of Appia Bio.
-
Where is Appia Bio headquartered?
Appia Bio is headquartered in Culver City, CA.
-
What is the size of Appia Bio?
Appia Bio has 36 total employees.
-
What industry is Appia Bio in?
Appia Bio’s primary industry is Biotechnology.
-
Is Appia Bio a private or public company?
Appia Bio is a Private company.
-
What is Appia Bio’s current revenue?
The current revenue for Appia Bio is .
-
How much funding has Appia Bio raised over time?
Appia Bio has raised $75.5M.
-
Who are Appia Bio’s investors?
Breakout Ventures, 8VC, Axial (San Francisco), Freeflow Ventures, and Kite Pharma are 5 of 8 investors who have invested in Appia Bio.
-
Who are Appia Bio’s competitors?
ImmPACT Bio, Century Therapeutics, Shoreline Biosciences, Adicet Bio, and Nkarta Therapeutics are some of the 6 competitors of Appia Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
